Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology leader advancing innovative oral therapies for hepatitis B virus (HBV) and microbiome-related disorders. This news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on ASMB's antiviral research programs and microbiome therapeutic platforms. Our curated news collection features press releases covering clinical trial progress, partnership announcements, and scientific presentations - all essential for informed analysis of the company's pipeline.
Key focus areas include updates on HBV core inhibitor candidates, microbiome strain development, and intellectual property advancements. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining scientific accuracy.
Bookmark this page for direct access to primary source materials and objective reporting on ASMB's pioneering work in oral antiviral therapies. Check regularly for the latest developments in this dynamic sector of precision medicine.
Assembly Biosciences (ASMB) has released interim results from its Phase 2 Study 211, which assesses the off-treatment response of its core inhibitor vebicorvir (VBR) in chronic HBV patients. The study, however, has not achieved a meaningful sustained virologic response (SVR), with 39 of 41 patients relapsing post-treatment. Specifically, only 4% of HBeAg negative and 6% of HBeAg positive patients maintained SVR. Despite these disappointing outcomes, Assembly Bio plans to proceed with a Phase 3 trial for vebicorvir as a chronic suppressive therapy in partnership with BeiGene, targeting the significant unmet need in HBV treatment.
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced that new clinical and preclinical data on its hepatitis B virus (HBV) core inhibitor portfolio will be presented at The Liver Meeting Digital Experience™ from November 13-16, 2020. Four abstracts, including two late-breaking posters, highlight research on the long-term safety of ABI-H0731 and associations between HBV pgRNA and HCC development. Assembly's HBV pipeline includes three core inhibitors, with vebicorvir showing superior antiviral activity in Phase 2 trials. Both vebicorvir and ABI-H2158 have received Fast Track designation from the FDA.
Assembly Biosciences (Nasdaq: ASMB) announced the appointment of Gina Consylman to its board of directors, effective October 20, 2020. Ms. Consylman brings over 25 years of experience in finance and accounting, currently serving as CFO at Ironwood Pharmaceuticals. Her extensive background includes roles at global biotech firms like Biogen and Ernst & Young LLP. With a solid foundation in finance and corporate strategy, her addition aims to strengthen Assembly's leadership team as it develops therapeutics targeting hepatitis B virus and microbiome-related diseases.
Assembly Biosciences (Nasdaq: ASMB) announced that Dr. John McHutchison has received the Advance 2020 Global Impact award for his significant contributions to curative therapies for hepatitis C virus (HCV). His dedication over 30 years has led to innovations now aimed at treating hepatitis B virus (HBV), affecting around 250 million people worldwide. Dr. McHutchison expressed his honor in receiving the award, emphasizing the need for better outcomes for HBV patients. The Advance Awards recognize global Australians contributing to diverse fields, including healthcare and technology.
Assembly Biosciences (Nasdaq: ASMB) participated in key conferences addressing hepatitis B virus (HBV). On October 5, 2020, Chief Scientific Officer William Delaney discussed critical gaps in HBV cure biomarkers. This was followed by a presentation from CEO John McHutchison at the H.C. Wainwright HBV Mini-Conference on October 20, 2020. The company aims to develop innovative therapies for HBV, which affects over 250 million globally. Current treatments only suppress the virus, highlighting the urgent need for effective therapies.
Assembly Biosciences, Inc. (ASMB) announced the grant of stock options to two new employees, totaling 31,520 shares at an exercise price of $17.29 per share, which was the closing price on October 1, 2020. These options have a ten-year term and vest over four years. The awards, approved by the Compensation Committee, are part of the 2020 Inducement Award Plan, as a material inducement for employment acceptance. The company is focused on developing therapeutics for hepatitis B virus (HBV) and microbiome-related diseases.
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced grants of stock options totaling 86,000 shares to five new employees, priced at $20.14 per share, the closing stock price on September 1, 2020. These options serve as material inducements for accepting employment at the company. The options have a ten-year term, vesting over four years with specific conditions for continued service and potential acceleration upon certain events. The compensation committee, comprised solely of independent directors, approved these awards outside of the stockholder-approved equity incentive plans.
Assembly Biosciences (Nasdaq: ASMB) presented crucial clinical data on its HBV core inhibitors vebicorvir (VBR) and ABI-H2158 during EASL's Digital International Liver Congress. Vebicorvir showed a favorable safety profile, achieving significant reductions in HBV DNA and pgRNA in patients with chronic HBV infections. Approximately 88% of participants in its Phase 2 study are projected to meet criteria for stopping therapy. ABI-H2158 exhibited improved potency against cccDNA formation. Both drugs have received Fast Track designation from the FDA.
Assembly Biosciences (Nasdaq: ASMB) announced the grant of stock options totaling 13,000 shares to two new employees at an exercise price of $23.08 per share, as of August 3, 2020. The options, which are part of the 2020 Inducement Award Plan, have a ten-year term and will vest over four years. This move aims to incentivize the new hires and is compliant with Nasdaq's regulations. The company focuses on developing therapeutics for hepatitis B virus and microbiome-related diseases.
Assembly Biosciences, Inc. (Nasdaq: ASMB) reported strong financial results for Q2 2020, highlighting a significant increase in collaborative research revenue to $39.4 million, up from $3.1 million in 2019, driven by a $36 million deferred revenue recognition. The company initiated key collaborations, notably with BeiGene, receiving $40 million upfront, with potential total payments of $500 million. Net income attributable to common stockholders was $7.5 million, marking a significant improvement from a net loss of $18.5 million the previous year. Cash reserves stood at $226.7 million, projected to fund operations into H2 2022.
